DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2pfhpq/global) has announced the addition of the "Global Fibromyalgia Drugs Market 2015-2019" report to their offering.
This report covers the present scenario and the growth prospects of the global fibromyalgia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of fibromyalgia.
There is no particular diagnostic test for detecting fibromyalgia, and physicians undertake differential diagnosis to check the presence of the syndrome. Currently in the US, only three drugs are approved to treat fibromyalgia. Off-label treatment is a popular option to treat fibromyalgia using analgesics, antidepressants, sedatives, neuroleptics, and muscle relaxants.
Pharmaceutical companies carry out small molecular changes on existing drugs and market them as me-too drugs. Vendors produce me-too drugs because of the increased expenditure associated with drug development and to overcome cost barriers. For instance, the CR formulation of Lyrica from Lyrica (pregabalin) by Pfizer is in phase III clinical trials. DS-5565 (mirogabalin) by Daiichi Sankyo is a me-too drug that is undergoing phase III clinical trials. These drugs are likely to be introduced in the market during the forecast period.
According to the report, though fibromyalgia has no known cure, approved drugs such as Lyrica, Savella, and Cymbalta are currently used to provide symptomatic treatment, especially in the US. The market presents immense potential for pharmaceutical companies to invest in the R&D of drugs that can cure the condition. In addition, Cymbalta and Lyrica have several adverse effects that lead to noncompliance and drug regimen discontinuation among individuals with the condition. In EMEA and APAC, healthcare settings and patients opt for off-label and OTC drugs to treat the condition. These drugs also have severe side effects. This provides vendors with a huge opportunity to develop drugs that have a better safety and efficacy profile.
Further, the report states that adverse effects of drugs leads to a reduction in the sales and revenue of the drugs and a decline in the market value.
Based on the chemical class of the drugs used to treat fibromyalgia, the market is segmented as follows:
- Serotonin norepinephrine reuptake inhibitors
- GABA analogs
- Eli Lilly
Other Prominent Vendors
- Daiichi Sankyo
- Innovative Med Concepts
- Meiji Seika
- Merck Sharp and Dohme
- Switch Biotech
- Zynerba Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/2pfhpq/global